Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database

Background and objective: Sacituzumab govitecan (SG), the first antibody-drug conjugate targeting human trophoblast cell-surface antigen 2 (Trop-2), has been approved by the Food and Drug Administration (FDA) for the treatment of advanced or metastatic breast cancer and urothelial cancer. However, there is currently a dearth of information regarding the safety profiles of SG in a large sample cohort. The objective of the present study is to investigate SG-related adverse events (AEs) in real-world settings leveraging the FDA Adverse Event Reporting System (FAERS) database to guide the safety management of clinical medication. Methods: The FAERS database was retrospectively queried to extract reports associated with SG from April 2020 to March 2023. To identify and evaluate potential AEs in patients receiving SG, various disproportionality analyses such as reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) were employed. Results: Overall, 2069 reports of SG as the “primary suspect” were identified. Noteworthy, SG was significantly associated with an increased risk of blood lymphatic system disorders (ROR, 7.18; 95% CI, 6.58–7.84) and hepatobiliary disorders (ROR, 2.68; 95% CI, 2.17–3.30) at the System Organ Class (SOC) level. Meanwhile, 61 significant disproportionality preferred terms (PTs) simultaneously complied with all four algorithms were adopted. Therein, anemia, thrombocytopenia, neutropenia, leukopenia, diarrhea, asthenia, alopecia, and electrolyte imbalance were consistent with the common AEs described in the clinical trials and specification of SG. Furthermore, unexpected significant AEs include colitis (ROR, 12.09; 95% CI, 9.1–16.08), heart rate increased (ROR, 5.11; 95% CI, 3.84–6.79), sepsis (ROR, 4.77; 95% CI, 3.59–6.34), cholestasis (ROR, 6.28; 95% CI, 3.48–11.36), blood bilirubin increased (ROR, 4.65; 95% CI, 2.42–8.94) and meningitis (ROR, 7.23; 95% CI, 2.71–19.29) were also be detected. The median time to onset of SG-related AEs was 14 [interquartile range (IQR), 7–52] days, with the majority occurring within the initial month of SG treatment. Conclusion: Our study validates the commonly known AEs and also found some potentially emerging safety issues related to SG in real-world clinical practice, which could provide valuable vigilance evidence for clinicians and pharmacists to manage the safety issues of SG.


Introduction
Triple-negative breast cancer (TNBC) is a poor prognostic breast cancer subtype characterized by the lack of estrogen and progesterone receptors and the amplification of the human epidermal growth factor receptor 2 (HER2) gene, comprises approximately 15%-20% of invasive breast cancers (Garrido-Castro et al., 2019;Giaquinto et al., 2022).TNBC is associated with higher and earlier recurrence and mortality rates in the operable (I-III) stages and shorter overall survival (OS) in the inoperable (IV) stage (Leon-Ferre and Goetz, 2023).Although immunotherapy has shown promising benefits in first-line clinical treatment, systemic chemotherapy remains the mainstay of standard care for previously treated metastatic TNBC (mTNBC) (Twelves et al., 2016;Winer et al., 2021;Gradishar et al., 2023).However, in second-line or beyond mTNBC setting, single-agent chemotherapy has shown low response rates (10%-15%), short progression-free survival (PFS) (2-3 months), and significant toxicity (Twelves et al., 2016;Khosravi-Shahi et al., 2018;Park et al., 2019).To date, treatment options for mTNBC patients who have received two or more regimens remain limited.Hence, advances in therapeutic options for these breast cancer patients are urgently needed.
Despite that, with the knowledge of the SG payload is a cytotoxic ingredient, safety concerns should also be taken into consideration along with its efficacy (Carey et al., 2022).Nevertheless, with the widespread use of SG in clinical practice, limited available information on AEs associated with SG treatment, which mainly comes from clinical trials.According to the safety analyses reported in the previous clinical trial and the instructions of SG, the most common adverse events (AEs) of SG were neutropenia, diarrhea, alopecia, anemia, nausea, fatigue, constipation, and vomiting (Kathpalia et al., 2023;Bardia et al., 2017;Spring et al., 2021;Rugo et al., 2022a).However, the safety profiles of SG therapy in real-world, large sample cohort settings, in particular, time to onset of AEs associated with SG treatment have not been well elucidated to date.
Therefore, we conducted this pharmacovigilance study to evaluate the post-marketing safety profile of SG in real-world settings leveraging the FDA Adverse Event Reporting System (FAERS) database to provide vigilance reference for clinicians and pharmacists to manage the safety issues of SG.

Study design and data source
This real-world, observational, retrospective pharmacovigilance study, performed from Quarter 2 (Q2) in 2020 to Q1 in 2023, was designed to explore SG related AEs leveraging the FAERS database.The FAERS database is a publicly accessible post-marketing safety surveillance database that including adverse event reports, product quality complaints, and medication error reports submitted by various occupational sources including health professionals, individual patients, pharmaceutical manufacturers, and lawyers (Fang et al., 2023).Despite FAERS is a US-centric database, it receives AE reports from around the global scope.Consequently, the extensive scale and worldwide reach of this open database render it highly appropriate for the evaluation of spontaneous reporting data.The FAERS database includes the following eight types of files: report sources (RPSR), demographic and administrative information (DEMO), drug information (DRUG), indications for use (INDI), start and end dates for reported drugs (THER), adverse events (REAC), patient outcomes (OUTC), and invalid reports (DELETED).All files are available on the FDA website (https:// fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html).Given that the FAERS databases are accessible to the public and patient records are anonymized and de-identified, neither informed consent nor ethical approval was involved.

Data extraction and mining
The data extraction and mining of the present study is illustrated in Figure 1.Generic names and brand names (sacituzumab govitecan, Trodelvy ® ) were applied to identify SG-related reports due to two variables, PROD_AI and DRUGNAME.Besides, in the light of FDA's recommendations, we eliminated duplicate reports filed by different people and institutions by choosing the latest FDA_ DT when the PRIMARYIDs were the same, and the higher PRIMARYID where the FDA_DT and the CASEID were the same.Generally, drugs reported within FAERS were categorized into four patterns: primary suspect (PS), secondary suspect (SS), concomitant (C), and interacting (I).In our investigations, exposure assessment was only considered when SG was documented as "primary suspect."The AE reports in FAERS database are coded according to Preferred Terms (PTs) in the Medical Dictionary for Regulatory Activities (MedDRA).The hierarchical structure of MedDRA allows for PTs to be categorized into the relevant System Organ Class (SOC), which is the highest level of MedDRA.Clinical characteristics, including demographics (age, gender), reporting characteristics (reporting year, region, and occupation of reporters), and indications of reports were collected.Meanwhile, serious outcomes were defined as death, life-threatening, hospitalization (initial or prolonged), disability, congenital anomaly, or other important medical event.
Additionally, the time to onset of specific AEs induced by SG was also assessed, calculated as the interval between the time of SG dosage initial (START_DT) and the time of AE onset (EVENT_ DT) (Shu et al., 2023a).Reports with dates missing or incorrect (drug usage time later than the time of event occurrence) were excluded.

Statistical analysis
Descriptive analysis was used to characterize all AEs reports in relation to SG treatment.In our investigations, both frequentist methods [reporting odds ratio (ROR) (van Puijenbroek et al., 2002) and proportional reporting ratio (PRR) (Evans et al., 2001)] and Bayesian methods [information component (IC) (Bate et al., 1998) and empirical Bayes geometric mean (EBGM) (Szarfman et al., 2002)] of disproportionality analysis were applied to identify the potential AE signals associated with SG, as a way to confirm our findings and reduce false-positive safety signals.A two-by-two contingency table is the framework for analyses (Supplementary Table S1).Besides, detailed equations and criteria for the four algorithms are presented in  standards aforementioned were deemed as significant positive indicators (Shu et al., 2023b).All data processing and statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, United States), Microsoft EXCEL Professional Plus 2013, and the GraphPad Prism 8.0 (GraphPad Software, CA, United States).

Descriptive analysis
During the surveillance period, from April 2020 to March 2023, a total of 4,713,940 reports were documented in the FAERS database, and 2069 (0.04%) reports were associated with SG medication [patient median (interquartile range, IQR) age, 56 (46-66) years].The specific demographic and clinical details are provided in Table 2. Gender data were available for 1,950 patients, and the proportion of women was 85.40%.Therein, middle-aged patients (18-65 years) tended to have a higher risk of SG related AEs (n = 732, 35.38%).Furthermore, a significant proportion of patients (n = 1,845, 89.17%) experienced serious outcomes, including hospitalizations (616 cases), deaths (544 cases), and lifethreatening situations (108 cases) with available follow-up data.From the perspective of reporting sources, 1,823 healthcare professionals-including doctors (52.15%) and pharmacists (35.69%)-submitted 88.11% of the AE reports, as compared to 245 consumers who reported 11.84% of the AEs, and 1unknown person who reported 0.05% of the AEs.According to the data presented in Table 2, the United States of America reported the most number of AE cases, with a total of 744, accounting for 35.96% of the whole.This was followed by France (n = 387, 18.70%), and Canada (n = 245, 11.84%).Besides, the number of reported AEsrelated to SG showed a gradual increase from 2020 to 2023.However, it is worth noting that except for 60.75% reported in 2022, the most reported year was the first quarter of 2023 (18.76%).

AE profiling of sacituzumab govitecan in disproportionality analysis
The proportion of positive signals for SG related AEs at the SOC level were shown in Figure 2.Meanwhile, specific signal strength of SG at the SOC level were described in Table 3. Statistically, we identified 26 organ systems that were involved in SG-induced AEs.In particular, the significant SOCs that met four criteria were investigations (SOC: 10022891, n = 604), blood and lymphatic system disorders (SOC: 10005329, n = 549), metabolism and nutrition disorders (SOC: 10027433, n = 247), hepatobiliary disorders (SOC: 10019805, n = 89), and congenital, familial and genetic disorders (SOC: 10010331, n = 12).Since FAERS is a collection of all medical and health-related PTs, it will also contain some non-drug-related AE signals that may be caused by disease progression or other causes.Therefore, in the present study, neoplasms benign, malignant and unspecified (incl cysts and polyps) (SOC: 10029104), injury, poisoning and procedural complications (SOC: 10022117), product issues (SOC: 10077536), surgical and medical procedures (SOC: 10042613) were not included for further analyses of SG-related AEs (Supplementary Table S2).

Algorithms
Calculation formulas Criteria

√
Abbreviation: ROR, reporting odds ratio; PRR, proportional reporting ratio; BCPNN, bayesian confidence propagation neural network; MGPS, multi-item gamma Poisson shrinker; EBGM, empirical Bayesian geometric mean; CI, confidence interval; χ 2 , chi-squared; IC, information component; IC025, the lower limit of the 95% one-sided CI, of the IC; EBGM05, the lower 95% onesided CI, of EBGM.Equation: a, number of reports containing both the target drug and the target adverse events; b, number of reports containing the target adverse drug reaction with other medications (except the target drug); c, number of reports containing the target drug with other adverse events (except the target adverse events); d, number of reports containing other medications and other adverse events.

Time-to-onset analysis
There were a total of approximately 814 AE reports that reported time of onset.The mean onset time was 49 days, and the median onset time was 14 (IQR, 7-52) days.Our data that the most onset time SG-related AEs was less than 30 days (n = 533, Of note, AEs might still have occurred after half a year for SG treatment, with a proportion of 2.56% (Table 2).Furthermore, we statistically analyzed the specific time of occurrence of PTs in each report, as detailed in Table 5, the time to onset of commonly reported AEs associated with SG were neutropenia 10.5 (IQR, 6-17) days, diarrhea 12 (IQR, 7-27) days, anemia 13.5 (IQR, 7-21) days, thrombocytopenia 14 (IQR, 6-39) days, respectively.Notably, the median onset time of heart rate increased was somewhat earlier than the other AEs [7 (IQR, 0-43.5)days], whereas pneumonia occurred relatively later [28 (IQR,) days].

Discussion
Sacituzumab govitecan, a first-in-class ADC targeting Trop-2, showed favorable tolerability and an impressive PFS and OS in patients with heavily pretreated mTNBC (Goldenberg et al., 2015; Frontiers in Pharmacology frontiersin.orgBardia et al., 2021a;Bardia et al., 2021b).Since the favorable results of single-agent SG established in the phase 2 TROPHY-U-01 (NCT03547973) trial and phase 3 TROPiCS-02 (NCT03901339) trial, the FDA has granted fast-track approval to SG for patients with locally advanced/metastatic urothelial carcinoma and unresectable locally advanced/metastatic hormone receptor-positive, HER2negative BC (Tagawa et al., 2021;Rugo et al., 2022b).Subsequently, the clinical practice and prescriptions of SG will inevitably increase.However, safety evidence of SG was limited to clinical trials, which provide only a narrow opinion of severe or even fatal issues (Bardia et al., 2019;Bardia et 2021a;Bardia et al., 2021b;Xu et al., 2023).Thus, the purpose of the present study is to decipher potential AEs associated SG to guide the summary of product characteristics, and to delineate the safety spectrum of SG as a reference for clinical medication.
In the present pharmacovigilance study, as shown in Table 2, SG-related AEs were increased significantly from 2020 2023, with the 2022 annual report (n = 1,257) almost four times as many as in 2021 (n = 359).The main reason for the yearly increase in SG-related AE reports may be attributed to the widespread clinical application of SG and the increased awareness of healthcare professionals about post-marketing safety surveillance of drugs.Meanwhile, approximately 88.11% of the AE reports were submitted by health professionals, which might be considered a reliable reporting source.The primary serious outcome of SG is death events, which may be due to the fact that TNBC is the highest recurrence and mortality rates subtype in breast cancer with a 5-year survival 8%-16% (Li et al., 2017;Howard and Olopade, 2021), and therefore mortality events might be more closely related to disease progression.a Emerging off-label AEs associated with sacituzumab govitecan were identified from the FAERS, database.
As described in Tables 3, 4, our disproportionality analyses suggested that the most significant SOCs for SG was congenital, familial and genetic disorders (ROR, 50.02; 95% CI, 28.21-88.68).However, at the SOC level of congenital, familial and genetic disorders, aplasia and uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene mutation is the main reported PTs, which were not recorded in the specification of SG or clinical trials, and more likely to be related to the patient's development problems or incomplete documentation of AEs information (TRODELVY).Noteworthy, the ROR for PTs of UGT1A1 gene mutation is 4378.02 (396.92-48289.81)high (Supplementary Table S3), this may be one of the major reasons why the SOC signal of congenital, familial and genetic disorders is so significant.The UGT1A1 enzyme plays a crucial role in the detoxification of SN-38 by glucuronidation, and the metabolites it produces are then eliminated from the body primarily by biliary excretion et al., 2017;Nelson et al., 2021).The results of previous studies indicated that patients with UGT1A1 homozygous*28/*28 genotype are at a higher risk of developing neutropenia while on SG therapy, and therefore patients known to have UGT1A1*28 homozygosity should be monitored closely (Bardia et al., 2021a;Rugo et al., 2021;Rugo et al., 2022a).
Besides, "investigations" and "blood and lymphatic system disorders" are also common and significant SOC associated with SG.Interestingly, the majority of PTs belonging to "investigations" were hematological AEs (e.g., white blood cell count decreased, haemoglobin abnormal, neutrophil count decreased), which were consistent with the safety results reported in the previous clinical trials ( Bardia et al., 2019;Bardia et al., 2021a;Bardia et al., 2021b).In the ASCENT trials, the incidence of febrile neutropenia, leukopenia, anaemia, neutropenia was 6%, 16%, 34%, and 63%, respectively (Bardia et al., 2021b).According to the SG insert, hematotoxicity is the primary AE, which may be caused by DNA double-strand breaks and apoptosis of hematopoietic cell progenitors due to the topoisomerase inhibition payload (SN-38) of SG.However, its overall incidence and severity were much lower than those observed with irinotecan (D'Arienzo et al., 2023;Mathijssen et al., 2001).For neutropenia, granulocyte colony-stimulating factor prophylaxis can be administered to patients at high risk for febrile neutropenia or a moderate risk but with risk factors (Spring et al., 2021).If not managed properly, severe hematologic AEs may lead to complications such as bleeding and possibly secondary infections up to sepsis.Therefore, clinicians should be vigilant in the early assessment and management of SG-related hematologic toxicity.
As for SOC of metabolism and nutrition disorders, hypokalaemia, electrolyte imbalance, and weight fluctuation are the main significant PT signals (Table 4).Previous reports have shown that severe diarrhea leads to loss of body fluids and electrolytes, which can lead to electrolyte imbalance, dehydration and renal insufficiency, and malnutrition (Do et al., 2022).In addition, nausea and vomiting can also lead to systemic complications metabolic imbalances and nutrient depletion (D'Arienzo et al., 2023).Hence, metabolism and nutrition disorders may be secondary complications due to gastrointestinal

AEs
Number a Median (Q1, Q3) toxicity induced by SG.Based on safety results from clinical trials (Bardia et al., 2021b;Rugo et al., 2022b), diarrhea occurred in about 60% of SG-treated patients, of whom about 10% had grade 3 events, which is thought to be related to the early dissociation of the drug from its antibody (off-target off-tumor toxicity).As per FDA label and clinical guidelines (Bossi et al., 2018;Bardia et al., 2021b;TRODELVY), if a patient develops acute diarrhea or early cholinergic syndrome (abdominal cramps, diarrhea, sweating, or excessive salivation) during or shortly after the infusion, intravenous atropine 0.4 mg every 15 min for two consecutive doses as needed.If ruled negative, loperamide is recommended in standard therapy.
The most commonly reported AEs during the SG treatment in mTNBC clinical trials were diarrhea, neutropenia, leukopenia, nausea, anemia, constipation, fatigue, alopecia, and vomiting (Bardia et al., 2019;Bardia et al., 2021a;Bardia et al., 2021b;Tagawa et al., 2021).In our disproportionality analyses, the significantly reported PTs for SG were anemia, neutropenia, leukopenia, diarrhea, asthenia, alopecia, which were mostly documented in the manufacturer's labeling and clinical trials.Furthermore, no significant disproportionate signals were found for nausea, constipation, and vomiting, several frequently reported adverse effects listed in the SG insert.The reason for these discrepancies may be that AEs are fairly common for all drugs in the FAERS database.The large number of reports of AEs associated with multiple drugs may suppress the signal score.Disproportionality requires that drug-specific AEs be reported more frequently (or less frequently).Thus, the absence of a signal does not mean that there are no associated AEs; it simply indicates that these AEs do not appear to be disproportionate (Sakaeda et al., 2013).
Excitingly, as shown in Table 4, our findings also raise some uncommon safety concerns.First, we detected some rare AEs with significant signals, included periorbital oedema, febrile neutropenia, neutropenic colitis, mucosal inflammation, hepatic lesion, gammaglutamyltransferase increased, cholinergic syndrome, pleural effusion, pneumonitis, and lymphedema, which were reported in the drug's label and clinical trials (TRODELVY).Second, we found some unexpected PTs with significant signals, including colitis, large intestine perforation, heart rate increased, cholecystitis acute, cholestasis, blood bilirubin increased, meningitis, sepsis, prerenal failure, and vein collapse.
Cardiotoxicity is a known potential AE of HER2-targeting ADC, to date, there were no reports about patients experiencing severe cardiac events related to SG treatment in clinical trials or real-world settings (Bardia et al., 2021a;Bardia et al., 2021b).However, in our disproportionality analyses, the PTs of heart rate increased showed a significant signal (n = 48, ROR = 5.11), suggesting that the risk of cardiac AEs related SG shouldn't be ignored and baseline assessment of risk factors for cardiovascular events remains crucial.On the other hand, anthracycline combined with taxane chemotherapy is the standard adjuvant treatment for TNBC, and cardiotoxicity is the main adverse reaction of anthracyclines (Lee et al., 2021).Thus, the increased heart rate may also be in part a long-term cardiac adverse effect of previous chemotherapy.Anyway, the knowledge of cardiovascular events related SG treatment is urgently needed to be further updated.
In the TROPiCS-02 phase 3 study, neutropenic colitis occurred in 0.5% of patients with hormone receptor-positive/HER2-negative advanced breast cancer, of note, one patient death was related to septic shock from SG associated neutropenic colitis (Rugo et al., 2022d).In the present disproportionality analyses, neutropenic colitis was also detected with a significant signal (n = 39, ROR = 156.97).Besides, off-labeling AEs of colitis (n = 48, ROR = 12.09) and large intestine perforation (n = 5, ROR = 8.23) were detected unexpectedly, which mostly related to the effects of the cytotoxic payload on the mucosal cells (D'Arienzo et al., 2023;Sandmeier et al., 2005).Thus, early recognition and proactive intervention of gastrointestinal toxicity is necessary because these effects can be lifethreatening or lead to poor quality of life.
The results of the present study indicated that the median time to onset of SG-related AEs was 14 (IQR, 7-52) days, with the majority of AEs occurring within the first month of SG treatment (n = 533, 25.76%), and AEs might still have occurred after half a year (Tables 2, 5).Therefore, longer follow-up periods are needed to observe SG-related AEs in future clinical trials.As described in Table 5, the median onset time of boxed warning AEs, neutropenia, and diarrhea, in a real-world setting was 10.5 (IQR,(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17) days and 12 (IQR, 7-27) days, respectively.This is similar to the median time to onset of neutropenia and diarrhea reported in the safety analyses results of the phase 3 ASCENT trial (neutropenia and diarrhea was 20 days and 12 days, respectively) (Spring et al., 2021).Taken together, these results suggested that clinicians and pharmacists should pay special attention to the labeled and potential AEs of patients, since which can be life-threatening, especially in the first half month of treatment.A better understanding of the real-world safety profile of SG in patients with mTNBC will lead to better compliance, fewer interruptions, and reflection on the desirable PFS and OS.
The main strength of this study is our ability to detect potential AEs that were not observed during the clinical trial stage for SG.As with previous studies based on pharmacovigilance databases, several limitations of the present study need to be addressed.First, due to the voluntary nature of reporting to FAERS database, the incidence and prevalence of AEs cannot be calculated, and underreporting is expected.Second, the presence of reports in the FAERS database is not causally relevant, so the results of the present study are only indicative of potential AEs, which means that clinicians and pharmacists should be vigilant.Third, multiple unmeasured confounders such as potential drug-drug interactions, comorbidities, and drug combinations, which might affect AEs, were not included in the data analysis.Besides, the disproportionality analysis neither quantified risk nor existed causality, but only estimated signal strength, which was only statistically significant.Therefore, prospective clinical trials are still required to verify their causal connection.
In conclusion, based on real-world data leveraging the FAERS, this study comprehensively investigated and identified AEs highly associated with SG by conducting disproportionality analysis.The AEs detected in the present study were generally consistent with the AEs introduced in the label, and some potential AEs, including colitis, large intestine perforation, heart rate increased, cholecystitis acute, cholestasis, blood bilirubin increased, meningitis, sepsis, prerenal failure, and vein collapse were also be revealed.Moreover, the median onset time of labeled and off-label AEs was reported here to provide vigilance reference for clinicians and pharmacists to optimize medication and manage the safety issues of SG.Given the exploratory character of our work, it is imperative to validate our findings in a prospective study and to elucidate the potential mechanisms and risk factors of AEs for improved risk management.

FIGURE 1
FIGURE 1Flow diagram for the selection of AEs associated with sacituzumab govitecan from FAERS database.

FIGURE 2
FIGURE 2Proportion of positive signal for sacituzumab govitecan related AEs at the System Organ Class (SOC) level.

Table 1 .
In the present study, drugrelated AE signals were identified based on the inclusion of signals with a minimum of three AE records associated with target drugs, and only AE signals that simultaneously met all four algorithm

TABLE 1
Four major algorithms used for signal detection.

TABLE 2
Summary of basic demographic and clinical information of reports associated with sacituzumab govitecan based on the FAERS database (From 1 April 2020 to 31 March 2023).

TABLE 2 (
Continued) Summary of basic demographic and clinical information of reports associated with sacituzumab govitecan based on the FAERS database (From 1 April 2020 to 31 March 2023).
AE, adverse event; 2023Q1, the first quarter of 2023.

TABLE 3
The signal strength of reports associated with sacituzumab govitecan at the system organ class (SOC) level in FAERS database.Values in bold indicates significant signals in four algorithms.PRR, proportional reporting ratio; ROR, reported odds ratio; IC, information component; EBGM, the empirical Bayes geometric mean; IC025 and EBGM05, lower limit of the 95% two-sided confidence interval for IC and EBGM, respectively.Signals are detected when all the following criteria are met: PRR ≥ 2 and χ2 > 4, lower limit of 95% CI of ROR > 1, IC025 > 0, EBGM025 > 2. Signal strength of reports associated with sacituzumab govitecan at the Preferred Terms (PTs) level in the FAERS database.

TABLE 4 (
Continued) Signal strength of reports associated with sacituzumab govitecan at the Preferred Terms (PTs) level in the FAERS database.

TABLE 5
Time to onset of AEs associated with sacituzumab govitecan.